Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC-5
2023-508707-20-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, oxaliplatin, irinotecan, fluorouracil and folinic acid in pancreatic cancer (PC), sponsored by Amsterdam University Medical Center. Primary endpoint: Progression-free survival. Planned start Apr 2024; status: authorised.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2023-508707-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508707-20-00.